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Abstract—Mitochondria densely populate cells in central nervous system providing essential energy for neurons
and influencing synaptic plasticity. Harm to these organelles can impair cognitive performance through damaged
neurotransmission and altered Ca2+ homeostasis. Impaired cognition could be one underlying factor which can
characterize major depressive disorder, a huge burden for society marked by depressed mood and anhedonia. A
growing body of evidence binds mitochondrial dysfunctions with the disease. Cognitive disturbances with differ-
ent severity are also observable in several patients, suggesting that damage or inherited alterations of mitochon-
dria may have an important role in depression. Since several different biological and environmental factors can
lead to depression, mitochondrial changes may represent a significant subgroup of depressive patients although
cognitive correlates can remain undiscovered without a specific focus. Hypothesis driven studies instead of
GWAS can pinpoint targets relevant only in a subset of depressed population. This review highlights results
mainly from candidate gene studies on nuclear DNA of mitochondrion-related proteins, including TOMM40,
MTHFD1L, ATP6V1B2 and MAO genes, also implicated in Alzheimer’s disease, and alterations in the mitochon-
drial genome to argue for endophenotypes where impaired mitochondrial function may be the leading cause
for depressive symptomatology and parallel cognitive dysfunction.
This article is part of a Special Issue entitled: Molecules & Cognition.  2017 The Authors. Published by Elsevier Ltd on behalf
of IBRO. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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energy demand through oxphos (Boekema and Braun,
2007; Wallace et al., 2010; Bansal and Kuhad, 2016).
The brain is especially dependent on mitochondrial
energy, since it only stores small amounts of glycogen
and, thus, its energy reserves are highly limited. As a
by-product of energy production, reactive oxygen species
are formed, however, mitochondria also contribute to the
defense against these free radicals producing protective
factors (Adam-Vizi and Tretter, 2013; Sinha et al., 2013;
Bansal and Kuhad, 2016). Another important feature of
mitochondria is their involvement in programed cell death,
apoptosis. Mitochondria can be involved in both extrinsic
and intrinsic apoptotic pathways, the latter being more
common in neurons (Kam and Ferch, 2000; Wyllie,
2010). It also became evident that, though sometimes
truly round-shaped organelles, mitochondria can form
connected tubules and their shape is regulated through
fusion and fission and disturbances of this dynamism
can lead to severe genetic diseases, e.g. Charcot–Mari
e–Tooth disease type 2A (Bereiter-Hahn and Voth,
1994; Zuchner et al., 2004; Chan, 2006, 2012).
The above-discussed functions make mitochondria
indispensable in network processes such as cognition. It
has been demonstrated in mice that intact mitochondrial
functions are required for proper synaptic plasticity
(Weeber et al., 2002; Levy et al., 2003; Picard and
McEwen, 2014). Mitochondria accumulate Ca2+ ions in
their matrices and participate in intracellular signaling pro-
cesses involving Ca2+-dependent mechanisms. One of
these processes is NMDA receptor-mediated long-term
potentiation, serving as the cellular model for memory
functions and higher order cognitive processes
(Giacomello et al., 2007; Mattson et al., 2008; Herring
and Nicoll, 2016). However, other mechanisms may also
play a role. Apoptosis, while especially important during
development (Roth and D’Sa, 2001), contributes to the
normal physiology of the adult brain, too. For example,
during learning in the Morris water maze, an animal model
for spatial learning and memory, adult-born dentate gran-
ule cells may be removed through apoptosis, if they prove
to be functionally unnecessary in networks (Deng et al.,
2010). In addition, studies suggested impaired mitochon-
drial functions in different neurodegenerative disorders
including Alzheimer’s, Parkinson’s, Huntington’s disease
and amyotrophic lateral sclerosis, where cognitive func-
tions are fundamentally impaired contributing to one of
the leading symptoms of these diseases [for a review
see (Golpich et al., 2017)].
In addition to the already discussed cognitive
dysfunctions, alterations in mitochondrion-mediated
mechanisms seem to contribute to depression,
considered a network-level disease too (Castren, 2005;
Morava and Kozicz, 2013; Tobe, 2013; Bansal and
Kuhad, 2016; Filipovic et al., 2017a, Shimamoto and
Rappeneau, 2017). Major depressive disorder (MDD) is
a high burden for society characterized by anhedonia
and depressed mood and often also accompanied by cog-
nitive disturbances. Previous studies found that depres-
sion was the initial symptom of mitochondrial diseases
(Fattal et al., 2007), mutations of mitochondrial ormitochondrion-related nuclear genes associated with
major depression (Onishi et al., 1997; Koene et al.,
2009), and mitochondrial disorder showed co-morbidity
with depression (Morava et al., 2010). Vice versa, mito-
chondrial mutations were also demonstrated in unipolar
depression patients (Munakata et al., 2007; Ben-
Shachar and Karry, 2008; Shao et al., 2008). From a cog-
nitive angle, although mood symptoms were considered
predominant in depression, and were the main focus of
both diagnosis and treatment in these disorders, recently,
cognitive symptoms and impairment in mood disorders
attracted increased attention and were gaining wider
recognition. It is important, however, that the role of most
candidate genes in depression is thought to depend on
stress exposure and/or traits and temperaments (Gonda
et al., 2009; Bagdy et al., 2012; Juhasz et al., 2014;
Sharma et al., 2016). Interestingly, the combination of
genes associated with cognition and others associated
with traits or temperaments also have emerged in gene–
gene interactions (Lazary et al., 2009; Lazary et al.,
2011). Cognitive dysfunction symptoms in major depres-
sion include attention, memory and executive function def-
icits contributing to decreased capacity for planning and
decision (Hammar and Ardal, 2009). Besides significantly
effecting function during acute depressive episodes, with
treatment approaches focusing on mood symptoms, cog-
nitive deficits often persist as residual symptoms after
restoring mood and contribute to lack of complete func-
tional recovery impairing social, academic and profes-
sional function in the long term, significantly decreased
quality of life, and increased risk of relapse (Beats et al.,
1996; Castaneda et al., 2008; Hammar and Ardal, 2009;
Marazziti et al., 2010). Cognitive symptoms have been
found to be present during 80–90% of depressive episode
length and also 40–45% of the length of remission phases
and executive function, verbal learning and memory defi-
cits can also be identified during euthymic periods empha-
sizing their involvement in the pathophysiology of the
disease and their importance in treatment (Biringer et al.,
2005; Smith et al., 2006; Conradi et al., 2011).
While depression and accompanying cognitive
impairment may not be exclusively of mitochondrial
origin, substantial damage to mitochondrial functions
can contribute to both of them. Thus, alterations in
mitochondrial proteins (encoded either in nuclear genes
or the mitochondrial genome) attenuating the functions
and capabilities of these organelles can lead to a
depressive phenotype which may be characterized by
altered cognitive functions. The present review
highlights some genes from mtDNA and from nuclear
DNA involved in primary (TOMM40 and MTHFD1L) and
secondary mitochondrial dysfunctions (ATP6V1B2 and
MAO) linking mitochondria with diminished cognitive
performance and major depression to argue for
endophenotypes in the disease and provide testable
biomarkers for further studies.MITOCHONDRIAL DNA
The human mtDNA encodes 2 ribosomal RNAs, 22
transfer RNAs and 13 proteins of the electron transport
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bases between the genes (Anderson et al., 1981;
Morava and Kozicz, 2013). MtDNA is always maternally
inherited and no recombination occurs (Byrne et al.,
2009). Consequently, mutations in mtDNA are in linkage
disequilibrium with all other variants. Thus, characterized
by a given set of variants nine major haplogroups evolved
and are present currently in the European population
(Byrne et al., 2009). MtDNA is prone to mutations, one
individual of every 200 is a pathogenic mutation carrier,
but usually without symptoms (Cree et al., 2009). In nor-
mal tissues all mtDNA in a given cell is identical, referred
to as homoplasmy. If mutations are present, a smaller or
larger subset of the mitochondria will contain them, thus,
cells will have both wild-type and mutant mitochondria,
called heteroplasmy (DiMauro and Schon, 2008). Usually
a certain ‘‘mutation load”, a certain degree of hetero-
plasmy of the cells is required to produce phenotypic
symptoms and threshold for disease manifestation is
high, around 80–90%. The reason for such a high thresh-
old may be that mitochondria can counteract deleterious
mutations. Different pathogenic mtDNA mutation-
carrying cells, after hybridization were able to restore res-
piratory activity suggesting that fusion of mitochondria
with polymorphisms at different sites could compensate
for the original defects (Ono et al., 2001; Chan, 2006).
An impact of mitochondrial genetic variations on
cognitive functions in mice was demonstrated by
Sharpley et al. (Sharpley et al., 2012). Interestingly, ani-
mals with heteroplasmy from two ‘‘normal” mitochondrial
genomes differing by 91 nucleotides performed worse in
the Barnes cognitive maze test than any of the homo-
plasmy group (Sharpley et al., 2012). In contrast, in
elderly adults’ rate of heteroplasmy at certain candidate
mutation sites in the complex I of the respiratory chain
showed associations with decreased cognitive perfor-
mance in the Modified Mini-Mental State Examination
(Tranah et al., 2015). Common variants in mtDNA were
also tested in a mitochondrial genome-wide association
study (GWAS) for cognitive performance. Altogether
1385 individuals (di- and monozygotic twins and non-
twin siblings) were included in the study, which found
no genome-wide significant associations between
mtDNA and cognitive performance. However, variants
(most of them in the NADH-ubiquinone oxidoreductase
chain 5 (ND5) gene) were nominally associated with
several cognitive test parameters (Byrne et al., 2009).
In another study, protective mitochondrial haplogroups
for Alzheimer’s disease were found (Ridge et al.,
2012). It was also demonstrated in a case-series that
mutations in the mtDNA are associated with cognitive
disturbances, namely, affected individuals with symp-
toms of mitochondrial disease showed worse perfor-
mance on several cognitive tests, among them the
Wechsler Adult Intelligence Scale subtests, parts of
Rey Auditory Verbal Learning Test, the Trail Making Test
and Stroop Color-Word Test (Inczedy-Farkas et al.,
2014). The results above suggest that variations in
mtDNA can influence cognitive functions, although com-
mon haplogroups and rare mutations seem to be distinct
phenomena with different effects.MtDNA mutations in depression were also
demonstrated. A deletion in mtDNA in a child was
associated with mitochondrial disease symptoms and
also with mild-moderate unipolar depression (Koene
et al., 2009). Using post-mortem brain samples from
human subjects none of the mitochondrial haplogroups
was associated with schizophrenia, bipolar disorder or
major depression (Sequeira et al., 2015). Major depres-
sion cases, however, showed rare homoplasmic muta-
tions with possible functional consequences in the ATP
synthase 8 (ATP8), ATP synthase 6 (ATP6), ND5 and
cytochrome b (CYTB) genes, while another subject with
depression demonstrated subthreshold heteroplasmy
rate at a variant in the displacement loop (D-loop) part
of mtDNA (Sequeira et al., 2015).
In summary, mutations in mtDNA may influence
cognitive performance and depression. However,
common mutations or rare ones below a certain
threshold were usually unable to show compelling
evidence for association with the phenotypes (though
small sample sizes may also play a role). In contrast,
these mutations were deleterious and caused severe
diseases above a certain threshold, with significantly
attenuated cognitive performance and mood disorders,
but also fatigue and other mitochondrion-associated
symptoms. This all-or-nothing type of response can be a
result of the compensatory capacities of these
organelles. But mitochondria also rely on nuclear genes
to maintain their normal capacities, like respiratory chain
functions, translation, transcription and protein
maintenance (DiMauro and Schon, 2008; Morava and
Kozicz, 2013). Polymorphisms within these nuclear
genes, (which are usually of small effect size, at least,
in depression) may have smaller, but less compensable
effects and can be responsible for different phenotypes,
like mild cognitive impairments (Mastroeni et al., 2016).TOMM40
The translocase of outer membrane (TOM) complex
imports most of the pre-proteins into mitochondria
(Larsen et al., 2017). TOM40, one of the seven subunits
of theTOMcomplex, is the central pore of themitochondrial
protein import apparatus (Gottschalk et al., 2014). It has an
essential role in the life of most eukaryotic organisms, and
studies suggest that reducing TOM40 levels causes mito-
chondrial dysfunction (Gottschalk et al., 2014).
The translocase of outer mitochondrial membrane 40
(TOMM40) gene is located on chromosome 19 in the
tight gene cluster TOMM40-APOE-APOC1-APOC4-
APOC2 with strong linkage disequilibrium (Gottschalk
et al., 2014). Apolipoprotein E (APOE) gene’s e4 allele
is a well-known genetic risk factor for the development
of Alzheimer’s disease (Corder et al., 1993; Farrer
et al., 1997; Gibson et al., 2000); and is also associated
with the onset (Butters et al., 2003) and severity of late-
life depression (Yen et al., 2007). TOMM40 is located only
15 kb upstream to APOE (Zeh, 2013), and GWASs also
suggested association between TOMM40 and Alzhei-
mer’s disease (Grupe et al., 2007; Harold et al., 2009;
Naj et al., 2010; Seshadri et al., 2010), but studies about
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sion are scarce (McFarquhar et al., 2014).
Some studies showed a connection between
TOMM40 and risk of late-onset Alzheimer’s disease,
cognitive performance and hippocampal atrophy
independently of APOE (Gottschalk et al., 2014); while
others couldn’t detect an APOE-independent effect of
TOMM40 on Alzheimer’s disease risk (Zeh, 2013;
Gottschalk et al., 2014). The mixed results could be partly
explained by technical and methodological differences
between approaches of different researcher groups and
the data collectively suggest the contribution of TOMM40
to Alzheimer’s disease and related phenotypes
(Gottschalk et al., 2014).
A study (McFarquhar et al., 2014) identified an asso-
ciation between TOMM40 rs2075650 and history of major
depression. Risk allele carriers with lifetime or current
depression showed decreased level of extraversion; and
the risk allele was also associated with cognitive deficits
(mild executive dysfunction, decrease in positive memory
intrusions) during current depression, and with altered
neuronal processing of sad faces in the cingulate cortex
(independently of depression). The researchers
suggested that TOMM40 risk allele carriers have altered
cingulate cortex functions, which could interact with
depression.
In a study of knock-down mice (Zeh, 2013) it was
found that the TOMM40+/ mice had decreased numbers
of dopaminergic neurons at the age of two compared to
their normal littermates. This result might relate to the
association between TOMM40 and depression through
the well-known dopaminergic dysfunction in the disease
(Dunlop and Nemeroff, 2007).
An interesting novel theory could add some important
information to this topic. The Alu neurodegeneration
hypothesis (Larsen et al., 2017) postulates an age-
related genetic mechanism contributing to mitochondrial
dysfunction, eventually leading to neuronal death. Alu ele-
ments are primate-specific retrotransposons within
TOMM40 with supposed fundamental role in primate evo-
lution, and possibly underlying the origin of higher brain
functions. The authors highlight that enhanced somatic
retrotransposon activity in neurologic networks correlates
with tissue-specific mitochondrial dysfunction which
increases with time and/or epigenetic changes, and thus,
contributes to neurodegenerative diseases. Through this
mechanism, depression may be the first symptom of later
life cognitive decline, with the first mild signs possibly
measurable by neurocognitive tasks.
Further investigations are needed to better
understand the relationship between TOMM40, cognitive
deficits and depression, but it seems plausible that
alterations of TOMM40 may play a role in the disorders
and mitochondrial functions.MTHFD1L
As a member of the folate-mediated one-carbon
metabolism, human mitochondrial monofunctional 10-
formyl-tetrahydrofolate synthetase (C1-THF synthase or
MTHFD1L) enzyme is tightly associated with the matrixside of mitochondrial inner membrane (Prasannan and
Appling, 2009), catalyzing the conversion of 10-formyl-
tetrahydrofolate into formate, both in embryonic (Pike
et al., 2010) and adult (Prasannan and Appling, 2009)
mammalian mitochondria. Formate then fluxes out to
get incorporated into the cytoplasmic branch of the
folate-dependent one-carbon metabolism, being thus
indispensable in cytoplasmic processes such as purine
biosynthesis, thymidylate biosynthesis, and the methyl
cycle (Pike et al., 2010).
In addition, MTHFD1L enzyme has been proven to be
important in maintaining proper mitochondrial function,
since its knockdown reduces both basal oxygen
consumption and electron transport chain capacity (Lee
et al., 2017).
The MTHFD1L gene encoding the MTHFD1L enzyme
has a single-nucleotide polymorphism (SNP),
rs11754661, the A allele of which has been identified in a
GWAS as a risk for Alzheimer’s disease, and its
significance survived the correction for genome-wide
multiple testing (Naj et al., 2010). This association between
rs11754661 A allele and Alzheimer’s disease was repli-
cated in two further studies (Ren et al., 2011; Ma et al.,
2012), but not in another (Ramirez-Lorca et al., 2011).
The A allele of MTHFD1L rs11754661 has also been
associated with depressive rumination (Eszlari et al.,
2016). Rumination denotes a cognitive response style to
stress: a process of thinking repetitively and passively
about the person’s own distress, depressed mood and
its possible causes and consequences, remaining fixated
on his or her feelings and concerns without any active
problem solving (Nolen-Hoeksema et al., 2008). Thus,
rumination is a cognitive risk factor for depression
(Nolen-Hoeksema et al., 2008). The A allele of the
MTHFD1L rs11754661 polymorphism is associated with
higher levels of both rumination and current depressive
symptoms, and a higher lifetime risk for depression; how-
ever, an asymmetry can be detected when taking into
account the mediative effect of one on the other. Namely,
the association of rs11754661 and depression is entirely
mediated by rumination (Eszlari et al., 2016). Conse-
quently, it can be assumed that this polymorphism of
the MTHFD1L gene by increasing rumination may be rel-
evant in the development of other disorders related to
rumination (Nolen-Hoeksema et al., 2008).
Furthermore, the A allele of rs11754661 has been
associated with high homocysteine (Hcy) levels
(Wernimont et al., 2011). Hcy is a non-protein amino acid
with manifold harmful effects. Its high level is associated
with major depression, reduced hippocampal volume, and
in healthy subjects impaired cognitive functions (Moustafa
et al., 2014). Hcy exerts its harmful effects via multiple
mechanisms, one of which is toxicity to mitochondria
(Moustafa et al., 2014; Du et al., 2016). Furthermore, Hcy
is part of the cytoplasmic branch of the folate-dependent
one-carbon metabolism (Pike et al., 2010). In the cyto-
plasm, catabolism of Hcy is dependent on folate (Pike
et al., 2010) and folic acid supplementation can effectively
reduce Hcy levels (Moustafa et al., 2014; Du et al., 2016).
Future testing is required to determine whether the
psychological and neuropsychiatric effects of this
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Hcy levels. Nevertheless, MTHFD1L gene and the
encoded mitochondrial protein MTHFD1L seems to be a
promising target in the background of cognitive domains
of depression.ATP6V1B2
Another possible candidate linking mitochondria,
cognition and depression is the ATPase H+
transporting V1 subunit B2 (ATP6V1B2) nuclear gene.
The A allele of rs1106634, an intronic SNP in the
ATP6V1B2 gene, which encodes the B subunit of the
vacuolar ATP-ase, has been implicated with a
suggestive significance in a meta-analysis of 3 genome-
wide association studies (GWASs) in major depression
(Shyn et al., 2011), while its T allele was implicated in a
genome-wide meta-analysis in bipolar disorder and
schizophrenia (Wang et al., 2010).
Although specific effects of ATP6V1B2 rs1106634 in
depression or cognition were not described before,
knowledge is accumulating on the role of this protein
with its possible involvement in neurotransmission. The
B subunit in the ATP-catalytic site of the vacuolar proton
pump ATP-ase is located in the V1 cytosolic domain in
a transmembrane complex and plays a role in creating a
proton gradient across membranes of synaptic vesicles,
mediating acidification of eukaryotic organelles including
endosomes and lysosomes, thus, playing a role in
receptor-mediated endocytosis, protein sorting, as well
as synaptic vesicle proton-gradient generation (Shyn
and Hamilton, 2010). It may play a role in neurotransmis-
sion, as the proton-motive force created by vacuolar ATP-
ases is involved in vesicle transport, reuptake and stor-
age, and vacuolar ATP-ases also play a role in retrieval
and reemployment of synaptic vesicles and energization
of regenerated vesicles (Nelson, 1991; van Hille et al.,
1994). Thus, even a small disruption in the electrochemi-
cal proton gradient may alter neurotransmitter release
(Egashira et al., 2015). Vacuolar ATP-ase, thought to be
a redox sensor and its function regulated by cellular redox
status, may also impact risk of depression through its
involvement in oxidative stress (Wang and Floor, 1998).
An association between a chromosome region containing
ATP6V1B2 genes and myeloperoxidase levels reflecting
prooxidative stress in a GWAS may support these
assumptions (Reiner et al., 2013). Vacuolar ATP-ase also
plays a role in maintaining developing cortical neural stem
cells in mouse models (Lange et al., 2011).
Recently, a study on a large general population
sample found evidence of an association between
rs1106634 A allele and lifetime depression risk and also
between this allele and worse neurocognitive
performance on the paired associated learning test but
not on the Stockings of Cambridge test. These results
suggest that this gene has an effect on hippocampal but
not on frontal dysfunction (Gonda et al., 2016), and pro-
pose a novel molecular mechanism in the long-term risk
for development of depression and possibly also its cog-
nitive symptoms. To emphasize the role of this variant
in cognitive dysfunction, previously a study reportedincreased ATP6V1B2 expression at both mRNA and pro-
tein levels in fibroblasts carrying a presenilin1 mutation,
which is one of the major causes hypothesized in familiar
Alzheimer’s disease (Coffey et al., 2014).
Mitochondria may be involved in the manifestation of
the effects of ATP6V1B2 in depression and in cognitive
symptoms of depression in several ways. Increased
reactive oxygen species formation and decreased ATP
production impair mitochondria (Bansal and Kuhad,
2016). Furthermore, ATP6V1B2 was found to be
expressed also in mitochondria (Jeon et al., 2011).
MtDNA depletion was associated with a wide range of
human illnesses and dysfunctional cellular states, with
cells remodeling mitochondrial functions and altering
mitochondrial protein composition (Jeon et al., 2011).
During such states ATP6V1B2 was reported to be upreg-
ulated, leading to downregulation of ATP synthesis (Jeon
et al., 2011). Impaired mitochondrial function disrupting
energy homeostasis and causing reduced ATP availability
may play a crucial role in depressive symptoms especially
cognitive dysfunction, lack of energy and fatigue
(Karabatsiakis et al., 2014). In a study investigating mito-
chondrial respiration, significantly impaired mitochondrial
function was reported including lower efficiency of cou-
pling of respiration related to ATP turnover, and signifi-
cant negative correlation between mitochondrial
respiration and severity of depression symptoms includ-
ing concentration difficulties, energy loss and fatigue sug-
gesting a role for mitochondrial dysfunction in the
pathophysiology of depression (Karabatsiakis et al.,
2014).
Furthermore, mitochondria are the chief reactive
oxygen species producer and disturbance of oxidative
homeostasis and oxidative stress is known to play a role
in depression and neurocognitive dysfunction as well
(Karabatsiakis et al., 2014). Reactive oxygen species also
have an adverse effect on mitochondrial DNA leading to
accumulating lesions and, thus, impairing ATP production
or respiratory chain function (Maes, 2011). Mitochondrial
dysfunctions including increased mtDNA defects,
decreased ATP production and enzyme activities show
a significant association with depression (Gardner et al.,
2003). Given the role of vacuolar ATP-ases as redox sen-
sors and their function being influenced by cellular redox
status, this may be a further pathway where the function
of ATP6V1B2 and mitochondria converges.MAO GENES
Monoamine oxidase genes encode the mitochondrial
isoenzymes monoamine oxidase A (MAO-A) and
monoamine oxidase B (MAO-B) and intracellularly both
are located in the outer mitochondrial membrane
(Squires, 1997). These isoenzymes vary in location and
selectivity in the human body. MAO-A is more likely dis-
tributed in fibroblast cells and placenta while MAO-B
can be found in platelets and lymphocytes. They are also
located in the brain (Bond and Cundall, 1977; Donnelly
and Murphy, 1977; Naoi et al., 2017). From the mitochon-
drial perspective, oxidative stress, through the production
of hydrogen peroxide, which is partially the result of MAO
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(Edmondson, 2014; Sorato et al., 2014). In addition,
MAO enzymes have important roles in catabolizing
monoamines serotonin, dopamine, noradrenaline, and
adrenaline, as well as diverse trace amines, while they
also play a role in degradation of different xenobiotics
through oxidative deamination (Edmondson et al., 2009;
Bortolato and Shih, 2011). MAO-A catalyzes degradation
of monoamines, especially serotonin, playing a crucial
role in mental disorders including unipolar depression
and anxiety disorders (Bagdy et al., 1986; Heninger
et al., 1996; Gingrich et al., 2003), underlining the impor-
tance of MAO-A enzymes in mental health and pathology.
To assess MAO-B functions in the context of depression,
cognitive dysfunction and the mitochondrion itself, it is
important to say that both isoenzymes are working in a
dichotomous way and prefer to degrade their specific
monoamines. Nonetheless, MAO-A and MAO-B can com-
pensate each other supporting the claim that there is
nothing like an absolute specificity (Chen et al., 2004).
While MAO-A shows more direct relationship toward
depression (Kersting et al., 2007), MAO-B tends to affect
emotional regulation, cognitive dysfunction, and disorders
like Alzheimer’s or Parkinson’s disease, autism spectrum
disorders (Dlugos et al., 2009; Chakraborti et al., 2016),
attention-deficit hyperactive disorder (ADHD) (Li et al.,
2008) and others. These results link both enzymes to
depression and cognitive performance.
From a genetic angle, in the MAO-A gene four
polymorphisms have shown associations with psychiatric
diseases (Dorszewska et al., 2013): (1) MAO-A (CA)n, a
dinucleotide repeat polymorphism in intron 2 (Black et al.,
1991); (2) a 23 base pair variable-number tandem repeat
(VNTR) polymorphism (Hinds et al., 1992); (3) Fnu4HI
and EcoRV restriction fragment length polymorphisms
(Lim et al., 1994); (4) MAO-A-uVNTR, a VNTR polymor-
phism upstream of MAO-A transcription initiation site
(Sabol et al., 1998; Gutierrez et al., 2004). The first three
were associated with psychiatric disorders (Bortolato and
Shih, 2011), the last was reported to affect sleep quality
and symptoms of depression (Brummett et al., 2007),
although contradictory results were also published failing
to demonstrate a relationship between MAO-A-uVNTR
and major depression or bipolar disorder (Syagailo et al.,
2001). MAO-A-uVNTR has been suggested to participate
in cognitive disturbances in one study, although results
did not survive correction for multiple testing (Yu et al.,
2005). Additionally, the presence of CC genotype at the
SNP, rs1137070, in the MAO-A gene predicted prolonged
reaction time between infancy and childhood in girls. This
attention deficit may be an effect of the altered availability
of monoamine substances, including dopamine and sero-
tonin that are also needed for brain development
(Lundwall and Rasmussen, 2016). In addition, a MAO-A
functional mutation was identified in a family with intellec-
tual and behavioral disorders suggesting a role for this
enzyme in cognitive functions (Piton et al., 2014). Further-
more, efficiency of the reversibleMAO-A inhibitormoclobe-
mide in elderly patients with dementia and depression also
raise the idea that cognitive dysfunction and depression
correlate with MAO-A functions (Amrein et al., 1999).In case of MAO-B, polymorphisms rs10521432 and
rs6651806 associated with negative emotional behavior,
while rs10521432 and rs66518806 seemed to influence
cognitive performance (Dlugos et al., 2009). Three other
SNPs could be related to ADHD (Li et al., 2008), while
the disease itself showed elevated co-occurrence in bipo-
lar and unipolar depressive patients compared to healthy
controls (Harmanci et al., 2016).
In summary, MAO overfunction appears to impair
mitochondria through oxidative stress, while different
polymorphisms may influence different facets of
cognitive performance and mood disorders suggesting
that MAO-A and MAO-B polymorphisms provide another
link between mitochondria, mood and cognition.CONCLUDING REMARKS
Our present review focusing on mutations linking
mitochondria, cognitive performance and depression,
suggests various ways in which genes affecting
mitochondrial functions can contribute to depression and
attenuated cognitive performance. In this regard there
may be differences between mtDNA polymorphisms,
which could remain compensated for a long time
through mitochondrial fusion, and nuclear ones, which
can have smaller, but constant effects. The different
combination of such loads in an individual can result in
specific depressive and cognitive symptoms, but can
also lead to an underlying risk for the disease with
impairments mild enough to remain unnoticed. Such
minor defects can be provoked by environmental stress,
as suggested by Morava et al. (2013), where the authors
hypothesized that stress may evoke otherwise unnotice-
able mitochondrial dysfunctions (probably caused by dif-
ferent genetic mutations) present in the individual,
explaining for the distinct resilience and coping capacities
characterizing each person (Morava and Kozicz, 2013).
Indeed, we also argued previously that in addition to
inherited or acquired genetic factors, environmental fac-
tors also contribute to depression, and their effects are
mediated by genetic polymorphisms (Bagdy et al.,
2012). Development of depression is typically and
strongly connected to environmental factors like child-
hood adversity and/or recent negative live events.
Genetic factors show weak direct effects (Mbarek et al.,
2017; Xie et al., 2017) and in general they become appar-
ent in the stress exposed groups or in gene-environment
interactions (Juhasz et al., 2014, 2015; Kovacs et al.,
2016a, 2016b, Bagdy et al., 2012). The risk genes
described in this review belong to a set of genetic factors,
where cognitive dysfunction is associated with the risk
genes directly, but subsequent stress exposure may fur-
ther sophisticate symptoms (Fig. 1). The presented evi-
dences suggest that nuclear genes in combination with
mitochondrial ones may shape together such endopheno-
types (Fig. 1).
Mitochondrion-related nuclear polymorphisms
associated with both depression and cognition, some
even at a genome-wide level, support our assumptions,
indicating that whatever the rate of contribution of
mitochondrial mutations, if mitochondrial processes are
Fig. 1. Different endophenotypes based on nuclear and mitochondrial gene mutations.Genetic
mutations in mitochondrial DNA or nuclear genes that are involved in mitochondrial functions may
result in altered functions of mitochondria, involving cellular and network-level functions. These
can manifest already in a disease phenotype but can also remain risk factors (first branch of
arrows) elicited only through environmental stress (second branch of arrows). As a result, a wide
scale of individual depressive and cognitive patterns with accompanying phenotypes (marked by
black lines on the scale) may exist in the population Identification of these endophenotypes in
individual patients and development of newer, selective therapeutics for them may help efforts of
precision medicine (marked by purple arrows).
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depression. Still, these cognitive symptoms in mood
disorders remain often overlooked, despite the fact that
they impose a serious burden on patients significantly
compromising quality of life and impairing daily function
in all domains.
From a therapeutic perspective, identification of
mitochondrial risks would be essential. Some currently
used antidepressants act as mitochondrial uncouplers
releasing respiratory control, enhancing activity of
ATPase and decreasing production of ATP. The
selective serotonin reuptake inhibitor fluoxetine, for
example, inhibited ATP production, and impacted
ATPase activity in multiple studies (de Oliveira, 2016).
In contrast, Filipovic et al. demonstrated elevated expres-sion of 63 mitochondrion-related pro-
teins following a chronic, 3-week-
long fluoxetine treatment by pro-
teomic analysis (Filipovic et al.,
2017b). Both papers suggested
effects of fluoxetine on mitochondrial
functions. At the same time, equally
long venlafaxine treatment caused
no significant alteration in any
mitochondrion-related genes in rat
hippocampal samples in our tran-
scriptomic study (unpublished data).
In addition, imipramine, a member of
the older tricyclic antidepressant
class induced an increase in cyto-
chrome b levels in mouse cortical
regions after chronic administration
(Huang et al., 1997), but again, ven-
lafaxine could not influence cyto-
chrome b levels in frontal cortical
regions of rats (Tamasi et al., 2014).
These differences between different
classes of antidepressants may result
from the distinct methodologies used,
but they may just as likely represent
consequences of different mecha-
nisms of actions. If such differences
indeed exist among therapeutics then
better characterization of mitochon-
drial involvement in depression and
its cognitive correlates and the paral-
lel selection of antidepressants based
on molecular evidences showing
effects at the individual molecular pat-
terns responsible could improve the
disappointing 50–60% response rates
to current interventions. For this, a
more detailed analysis of therapeutics
and causal genes in the disease, like
those presented here, are both
needed, with such an approach repre-
senting the next step toward precision
medicine in depression and accompa-
nying cognitive symptoms.
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